The U.S. Food and Drug Administration (FDA) has recently issued a stern warning regarding the purchase and use of several over-the-counter eye drop products from well-known brands. These brands include CVS Health Corporation (CVS), Leader (owned by Cardinal Health, Inc. (CAH)), Rugby (also a Cardinal Health brand), Rite Aid Corp. (RADCQ), Target Corporation’s Up&Up, and Velocity Pharma.
The FDA has raised concerns about the potential risk of eye infections associated with these products, which, in severe cases, could lead to partial vision loss or even blindness.
Consumers who experience signs or symptoms of an eye infection after using these eye drops have been strongly urged by the healthcare regulator to seek immediate medical attention or consult with their healthcare provider.
The FDA has discovered unsanitary conditions and positive bacterial test results in the critical drug production areas of the manufacturing facility responsible for these eye drop products. As a result, the FDA recommended on October 25th that the manufacturer recall all batches of the affected products. Consumers are advised to properly dispose of these products.
Major retail chains, including CVS, Rite Aid, and Target, have taken swift action and removed the implicated products from their shelves and online platforms. CVS, upon receiving notification from the FDA, immediately ceased the sale of all products supplied by Velocity Pharma and offered a full refund to customers returning the product. However, products branded as Leader, Rugby, and Velocity may still be available in stores and online. Consumers are strongly advised to refrain from purchasing these products.
As of now, the FDA has not received any reports of adverse events or eye infections associated with the use of these products. The agency encourages healthcare professionals and patients to report any adverse events or quality problems experienced with any medicine to the FDA’s MedWatch Adverse Event Reporting program to ensure swift identification and rectification of potential safety issues.
In the ophthalmic drug space, notable firms include Regeneron Pharmaceuticals, Inc. (REGN), Novartis AG (NVS), Bausch Health Companies Inc. (BHC), Roche Holding AG (RHHBY), and Pfizer Inc. (PFE).
Regeneron Pharmaceuticals, Inc. (REGN) is known for its eye condition treatment, Eylea.
Novartis AG (NVS) is involved in ophthalmology through its Alcon division.
Bausch Health Companies Inc. (BHC) offers a range of ophthalmic products, including its flagship Bausch + Lomb contact lens offerings.
Roche Holding AG (RHHBY) is involved in ophthalmology through Genentech.
Pfizer Inc. (PFE) provides ophthalmic drugs and products via its unit Pfizer Ophthalmics.
Read Next: FDA Bans Vuse Menthol E-Cigs: Why Some Vapes Like Elf Bars Avoid Scrutiny, Others Don’t
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock
——————————————————————————————————————
Title: Popular Eye Drop Products from CVS, Target, Cardinal Health, and More Pose Grave Risks, FDA Warns
Introduction:
The U.S. Food and Drug Administration (FDA) has recently issued a stern warning about the potential dangers associated with the purchase and use of over-the-counter eye drop products from prominent brands like CVS, Target, Cardinal Health, and more. This article explores the risks posed by these products and highlights the FDA’s recommendations for consumers and retailers. Read on to discover the reasons behind the FDA’s warning and the actions taken by major retail chains in response to the issue.
Are Your Eyes At Grave Risk?
The recent FDA warning has raised serious concerns about the use of specific over-the-counter eye drop products. The agency has cautioned consumers against purchasing and using these products due to the potential risk of eye infections. In severe cases, these infections could lead to partial vision loss or even blindness. To protect themselves, consumers are strongly advised to be aware of the brands associated with this warning, including CVS Health Corporation (CVS), Leader (owned by Cardinal Health, Inc. (CAH)), Rugby (also a Cardinal Health brand), Rite Aid Corp. (RADCQ), Target Corporation’s Up&Up, and Velocity Pharma.
Unsanitary Manufacturing Conditions
The FDA has discovered unsanitary conditions and positive bacterial test results from the critical drug production areas of the manufacturing facility responsible for these eye drop products. As a result, on October 25th, the FDA recommended that the manufacturer recall all affected batches. Consumers are urged to properly dispose of these products to ensure their safety. It’s essential to note that as of now, the FDA has not received any reports of adverse events or eye infections associated with the use of these products.
Retailers’ Response
In response to the FDA warning, major retail chains such as CVS, Rite Aid, and Target have taken swift action to protect their customers. These chains have removed the implicated eye drop products from their shelves and online platforms. Upon receiving notification from the FDA, CVS immediately stopped the sale of all products supplied by Velocity Pharma. CVS has also offered a full refund to customers returning the product. However, products branded as Leader, Rugby, and Velocity may still be available in stores and online. Consumers are strongly advised against purchasing these products.
The Importance of Reporting Adverse Events
The FDA encourages healthcare professionals and patients to report any adverse events or quality problems experienced with any medicine through the FDA’s MedWatch Adverse Event Reporting program. By doing so, potential safety issues can be swiftly identified and rectified, ensuring the well-being of the public.
Notable Firms in the Ophthalmic Drug Space
Apart from the brands mentioned in the FDA warning, several notable firms operate in the ophthalmic drug space. Regeneron Pharmaceuticals, Inc. (REGN) is known for its eye condition treatment, Eylea. Novartis AG (NVS) actively participates in ophthalmology through its Alcon division. Bausch Health Companies Inc. (BHC) offers a range of ophthalmic products, including the well-known Bausch + Lomb contact lens offerings. Roche Holding AG (RHHBY) is involved in ophthalmology through its subsidiary, Genentech. Pfizer Inc. (PFE) provides ophthalmic drugs and products through its unit Pfizer Ophthalmics.
Conclusion
The FDA’s warning regarding the potential risks associated with certain eye drop products from popular brands like CVS, Target, Cardinal Health, and more highlights the critical importance of consumer safety. By understanding the risks involved and taking appropriate action, such as disposing of these products and refraining from purchasing them, consumers can protect their eyesight. Retailers play an equally vital role in ensuring customer well-being by promptly removing the implicated products from their shelves and online platforms. Together, we can create a safer environment for all those in need of eye care products.
